Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26199517 | 0.90 | MAP1LC3B (0.43) | FURINHTTMAP1LC3BKMT2AMEN1 | |
| SCHEMBL19591557 | 0.85 | FURIN (0.49) | FURINHTT | |
| SCHEMBL9943154 | 0.84 | FURIN (0.46) | FURINHTTMAP1LC3B | |
| SCHEMBL22336596 | 0.84 | FURIN (0.44) | FURINHTTMAP1LC3BRAB9ATP53 | |
| SCHEMBL21649698 | 0.84 | FURIN (0.44) | FURINHTTMAP1LC3BRAB9ATP53 | |
| SCHEMBL22064590 | 0.84 | FURIN (0.51) | FURINHTTALDH1A1KMT2AMEN1 | |
| SCHEMBL27434009 | 0.83 | TRPV1 (0.39) | FURINHTTMAP1LC3B | |
| SCHEMBL27291528 | 0.83 | FURIN (0.49) | FURINHTTKMT2AMEN1POLB | |
| SCHEMBL24829476 | 0.82 | FURIN (0.47) | FURINHTT | |
| SCHEMBL21569760 | 0.82 | FURIN (0.47) | FURINHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | FURIN 2674/4885HTT 696/4885MAP1LC3B 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.